Evidence map›Paper›PMID 23435697›Full record

ReviewAIDS and behavior2013

Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials.

K Rivet Amico, Leila E Mansoor, Amy Corneli, Kristine Torjesen, Ariane van der Straten

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in AIDS and behavior, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02611362 (A Multilevel Gaming Intervention for Persons on PrEP), which is not on this map. Cited by 92 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed, 1 pooled it
11.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02611362 nacompletednot on this mapstarted 2015, after this paper: background citation

A Multilevel Gaming Intervention for Persons on PrEP

TypeinterventionalSponsorRhode Island HospitalRan2015 to 2019Enrolled82ConditionsMSM, PrEP, HIV RiskArmsIMB Gaming Intervention
3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 1 synthesis or guideline pooled it, 144 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

K Rivet AmicoCenter for Health Interventions and Prevention, University of Connecticut, Storrs, CT, USA. rivetamico@comcast.net
Leila E Mansoor
Amy Corneli
Kristine Torjesen
Ariane van der Straten
Family Health International 360 · USRTI International · USUniversity of Connecticut · USUniversity of KwaZulu-Natal · ZA

Funding

Microbicide Trials NetworkUM1AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2011 to 2021
$175.0M
Microbicide Trials NetworkU01AI068633 · NIAID · MAGEE-WOMEN'S RES INST AND FOUNDATION · PI HILLIER, SHARON L. · 2006 to 2010
$77.0M
The Viral Set Point in HIV-1 Subtype C InfectionU19AI051794 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI ABDOOL KARIM, SALIM S · 2002 to 2007
$22.5M
TUBERCULOSIS SUPPLEMENTD43TW000231 · FIC · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ABDOOL KARIM, QUARRAISHA · 1993 to 2014
$13.1M
FIC NIH HHS D43 TW000231FIC NIH HHS D43TW00231NIAID NIH HHS 5UM1AI068633NIAID NIH HHS AI51794NIAID NIH HHS U19 AI051794NIAID NIH HHS UM1 AI068633
6 · The paper itself

Abstract

Adherence is a critical component of the success of antiretroviral-based pre-exposure prophylaxis (PrEP) in averting new HIV-infections. Ensuring drug availability at the time of potential HIV exposure relies on self-directed product use. A deeper understanding of how to best support sustained PrEP adherence remains critical to current and future PrEP efforts. This paper provides a succinct synthesis of the adherence support experiences from four pivotal PrEP trials--Centre for the AIDS Programme of Research in South Africa (CAPRISA) 004, FEM-PrEP, Iniciativa Prophylaxis (iPrEx), and Vaginal and Oral Interventions to Control the Epidemic (VOICE). Notwithstanding variability in the design, population/cohort, formulation, drug, dosing strategy, and operationalization of adherence approaches utilized in each trial, the theoretical basis and experiences in implementation and monitoring of the approaches used by these trials provide key lessons for optimizing adherence in future research and programmatic scale-up of PrEP. Recommendations from across these trials include participant-centered approaches, separating measurement of adherence from adherence counseling, incorporating tailored strategies that go beyond education, fostering motivation, and addressing the specific context in which an individual incorporates and negotiates PrEP use.

Indexed as

Medication AdherenceAnti-HIV AgentsClinical Trials as TopicCounselingHIV InfectionsHumansMaleMotivationMulticenter Studies as TopicRandomized Controlled Trials as TopicAnti-HIV Agents

Identifiers

PMID23435697
PMCPMC3672509
OpenAlexW1983020368

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.